Hennion & Walsh Asset Management, Inc. Karuna Therapeutics, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 10, 2024	BUY	$161.01 - $317.85 $118,986 - $234,891	739 Added 9.21%	8,763 $2.77 Million
Q3 2023 Oct 27, 2023	BUY	$164.66 - $218.08 $35,895 - $47,541	218 Added 2.79%	8,024 $1.36 Million
Q2 2023 Aug 09, 2023	SELL	$176.32 - $240.22 $39,319 - $53,569	-223 Reduced 2.78%	7,806 $1.69 Million
Q1 2023 Apr 20, 2023	BUY	$161.33 - $204.36 $18,391 - $23,297	114 Added 1.44%	8,029 $1.46 Million
Q4 2022 Jan 12, 2023	BUY	$191.53 - $236.82 $198,042 - $244,871	1,034 Added 15.03%	7,915 $1.56 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $380,282 - $852,234	3,072 Added 80.65%	6,881 $1.55 Million
Q2 2022 Jul 19, 2022	BUY	$93.97 - $143.33 $357,931 - $545,943	3,809 New	3,809 $482,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.